Lesson plan
Leniolisib
Leniolisib, sold under the brand name Joenja, is an anti-cancer medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is a kinase inhibitor that is taken by mouth. The most common side effects include headache, sinusitis, and atopic dermatitis. Leniolisib was approved for medical use in the United States in March 2023, in the United Kingdom in September 2024, and in the European Union in May 2026. It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration considers it to be a first-in-class medication. In 2025 NICE approved it for use in the British NHS.
Article summary
Leniolisib, sold under the brand name Joenja, is an anti-cancer medication used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is a kinase inhibitor that is taken by mouth. The most common side effects include headache, sinusitis, and atopic dermatitis. Leniolisib was approved for medical use in the United States in March 2023, in the United Kingdom in September 2024, and in the European Union in May 2026. It is the first approved medication for the treatment of activated PI3K delta syndrome. The US Food and Drug Administration considers it to be a first-in-class medication. In 2025 NICE approved it for use in the British NHS.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.